Spero Therapeutics Inc (NASDAQ:SPRO) reported fourth-quarter and full-year 2025 financial results that delivered a significant positive surprise on profitability, driving a sharp after-hours rally in its stock price. The clinical-stage biopharmaceutical company's earnings per share dramatically outperformed analyst expectations, while revenue, though not directly comparable to a zero estimate, came in at a substantial level.
Earnings Surprise and Financial Snapshot
The standout figure from the report was the company's non-GAAP earnings per share (EPS). For the quarter ended December 31, 2025, Spero reported EPS of $0.53. This result starkly contrasted with the consensus analyst estimate, which had projected a loss of $0.204 per share. The company reported revenue of $41.3 million for the quarter. While analyst estimates for Q4 revenue were listed as $0.0—a figure that typically indicates a lack of formal consensus or an expectation of negligible collaboration revenue—the reported $41.3 million represents a meaningful inflow, primarily attributed to collaboration agreements.
The financial performance for the period can be summarized as follows:
- Reported Q4 2025 EPS (Non-GAAP): $0.53
- Analyst Estimate for Q4 2025 EPS: -$0.204
- Reported Q4 2025 Revenue: $41.3 million
- Analyst Estimate for Q4 2025 Revenue: $0.0 million
Market Reaction to the Beat
The market's immediate reaction was decisively positive. Following the earnings release, Spero's stock surged approximately 4.6% in after-hours trading. This move suggests investors were encouraged by the unexpected profitability and the solid revenue figure, which may provide the company with an extended financial runway. The positive after-hours action stands in contrast to the stock's performance over recent weeks, which had been relatively muted.
Business Update and Pipeline Focus
Beyond the financials, the core of Spero's update centered on its lead pipeline candidate, tebipenem HBr. The company announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral antibiotic, seeking approval for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. This resubmission is a critical regulatory step forward for the company's most advanced asset. Spero's pipeline also includes SPR720, a candidate for nontuberculous mycobacterial pulmonary disease, and SPR206, an intravenous agent targeting multi-drug resistant bacterial infections.
Looking Ahead: Estimates vs. Pipeline Milestones
Analyst projections for the coming periods reflect the uncertain and milestone-driven nature of clinical-stage biotech finance. For the first quarter of 2026, the consensus EPS estimate is a loss of $0.18, with no sales estimate provided. For the full year 2026, analysts, on average, forecast an EPS loss of $0.68 and sales of approximately $816,000. These sales estimates are likely tied to potential milestone payments or modest collaboration revenue, not the commercial launch of a product. The company did not provide specific financial guidance for 2026 in the press release, making a direct comparison to these analyst estimates not possible. The key near-term outlook for Spero remains the regulatory review process for tebipenem HBr and the progression of its other clinical programs.
For a detailed view of Spero Therapeutics' historical earnings and future analyst projections, you can review the earnings history and analyst estimates & forecasts.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any security. Investing in equities, particularly clinical-stage biopharmaceutical companies, involves substantial risk, including the potential loss of principal. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.